These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16103866)

  • 21. Treating diabetic peripheral neuropathic pain.
    Lindsay TJ; Rodgers BC; Savath V; Hettinger K
    Am Fam Physician; 2010 Jul; 82(2):151-8. PubMed ID: 20642268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with dual action antidepressants in different chronic pain syndromes.
    Briley M
    Hum Psychopharmacol; 2004 Oct; 19 Suppl 1():S21-5. PubMed ID: 15378667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of duloxetine in fibromyalgia.
    Ursini F; Pipicelli G; Grembiale RD
    Clin Ter; 2010; 161(4):391-5. PubMed ID: 20931165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duloxetine status.
    Fishbain DA
    Pain Med; 2007 Sep; 8 Suppl 2():S25-6. PubMed ID: 17714112
    [No Abstract]   [Full Text] [Related]  

  • 26. Predictors of duloxetine versus other treatments among veterans with diabetic peripheral neuropathic pain: a retrospective study.
    Zhao Y; Liu J; Zhao Y; Thethi T; Fonseca V; Shi L
    Pain Pract; 2012 Jun; 12(5):366-73. PubMed ID: 21951753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
    Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
    J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetic/pharmacodynamic models for duloxetine in the treatment of diabetic peripheral neuropathic pain.
    Yuen E; Gueorguieva I; Bueno-Burgos L; Iyengar S; Aarons L
    Eur J Pain; 2013 Mar; 17(3):382-93. PubMed ID: 22893563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia.
    Wu SC; Wrobel JS; Armstrong DG
    Pain Med; 2007 Sep; 8 Suppl 2():S33-42. PubMed ID: 17714114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
    Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
    Arnold LM; Meyers AL; Sunderajan P; Montano CB; Kass E; Trivedi M; Wohlreich MM
    Ann Clin Psychiatry; 2008; 20(4):187-93. PubMed ID: 19034749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.
    Bymaster FP; Beedle EE; Findlay J; Gallagher PT; Krushinski JH; Mitchell S; Robertson DW; Thompson DC; Wallace L; Wong DT
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4477-80. PubMed ID: 14643350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
    Russell JM; Weisberg R; Fava M; Hartford JT; Erickson JS; D'Souza DN
    Depress Anxiety; 2008; 25(7):E1-11. PubMed ID: 17587217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Duloxetine, a new therapeutic option for diabetic peripheral neuropathic pain].
    Ziegler D
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S284-8. PubMed ID: 17139588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New drug for neuropathic pain.
    FDA Consum; 2004; 38(6):2. PubMed ID: 15675007
    [No Abstract]   [Full Text] [Related]  

  • 36. Duloxetine Eli Lilly.
    Anttila S; Leinonen E
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1217-21. PubMed ID: 12211418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of duloxetine in the management of diabetic peripheral neuropathic pain.
    Smith T; Nicholson RA
    Vasc Health Risk Manag; 2007; 3(6):833-44. PubMed ID: 18200804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New and emerging treatment options for neuropathic pain.
    Gidal BE
    Am J Manag Care; 2006 Jun; 12(9 Suppl):S269-78. PubMed ID: 16774459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of the symptomatic treatment of diabetic neuropathy.
    Wright JM
    Pharmacotherapy; 1994; 14(6):689-97. PubMed ID: 7885972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Painful diabetic neuropathy: treatment and future aspects.
    Ziegler D
    Diabetes Metab Res Rev; 2008; 24 Suppl 1():S52-7. PubMed ID: 18395890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.